Francesco Petrella1,2, Davide Radice3, Juliana Guarize1, Gaia Piperno4, Cristiano Rampinelli5, Filippo de Marinis6, Lorenzo Spaggiari1,2. 1. Department of Thoracic Surgery, IRCCS European Institute of Oncology, 20141 Milan, Italy. 2. Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, 20141 Milan, Italy. 3. Department of Biostatistcs, IRCCS European Institute of Oncology, 20141 Milan, Italy. 4. Department of Radiotherapy, IRCCS European Institute of Oncology, 20141 Milan, Italy. 5. Department of Radiology, IRCCS European Institute of Oncology, 20141 Milan, Italy. 6. Department of Thoracic Oncology, IRCCS European Institute of Oncology, 20141 Milan, Italy.
Abstract
BACKGROUND: the aim of this paper is to quantify multidisciplinary team meeting (MDT) impact on the decisional clinical pathway of thoracic cancer patients, assessing the modification rate of the initial out-patient evaluation. METHODS: the impact of MDT was classified as follows: confirmation: same conclusions as out-patient hypothesis; modification: change of out-patient hypothesis; implementation: definition of a clear clinical track/conclusion for patients that did not receive any clinical hypothesis; further exams required: the findings that emerged in the MDT meeting require further exams. RESULTS: one thousand consecutive patients evaluated at MDT meetings were enrolled. Clinical settings of patients were: early stage lung cancer (17.4%); locally advanced lung cancer (27.4%); stage IV lung cancer (9.8%); mesothelioma (1%); metastases to the lung from other primary tumors (4%); histologically proven or suspected recurrence from previous lung cancer (15%); solitary pulmonary nodule (19.2%); mediastinal tumors (3.4%); other settings (2.8%). CONCLUSIONS: MDT meetings impact patient management in oncologic thoracic surgery by modifying the out-patient clinical hypothesis in 10.6% of cases; the clinical settings with the highest decisional modification rates are "solitary pulmonary nodule" and "proven or suspected recurrence" with modification rates of 14.6% and 13.3%, respectively.
BACKGROUND: the aim of this paper is to quantify multidisciplinary team meeting (MDT) impact on the decisional clinical pathway of thoracic cancerpatients, assessing the modification rate of the initial out-patient evaluation. METHODS: the impact of MDT was classified as follows: confirmation: same conclusions as out-patient hypothesis; modification: change of out-patient hypothesis; implementation: definition of a clear clinical track/conclusion for patients that did not receive any clinical hypothesis; further exams required: the findings that emerged in the MDT meeting require further exams. RESULTS: one thousand consecutive patients evaluated at MDT meetings were enrolled. Clinical settings of patients were: early stage lung cancer (17.4%); locally advanced lung cancer (27.4%); stage IV lung cancer (9.8%); mesothelioma (1%); metastases to the lung from other primary tumors (4%); histologically proven or suspected recurrence from previous lung cancer (15%); solitary pulmonary nodule (19.2%); mediastinal tumors (3.4%); other settings (2.8%). CONCLUSIONS:MDT meetings impact patient management in oncologic thoracic surgery by modifying the out-patient clinical hypothesis in 10.6% of cases; the clinical settings with the highest decisional modification rates are "solitary pulmonary nodule" and "proven or suspected recurrence" with modification rates of 14.6% and 13.3%, respectively.
Entities:
Keywords:
multidisciplinary team meeting; thoracic oncology; tumor boards
Authors: Stefania Rizzo; Maria Del Grande; Vittoria Espeli; Anastasios Stathis; Gabriele Maria Nicolino; Filippo Del Grande Journal: Insights Imaging Date: 2021-05-26